Full Range C-reactive Protein (Ultra-sensitive CRP+Conventional CRP) Detection Kit (Immunoturbidimetric Method) - NMPA Registration 粤械注准20222401915
Access comprehensive regulatory information for Full Range C-reactive Protein (Ultra-sensitive CRP+Conventional CRP) Detection Kit (Immunoturbidimetric Method) in the China medical device market through Pure Global AI's free database. This Class II medical device is registered under NMPA registration number 粤械注准20222401915 and owned by Shenzhen Lifotronic Technology Co., Ltd.. The device was approved on December 05, 2022.
This page provides complete registration details including registrant information, province location (Guangdong), intended use, and regulatory compliance data from the official China NMPA medical device database. Pure Global AI offers free access to China's complete medical device registry, helping global MedTech companies navigate NMPA regulations efficiently.
It is used for the quantitative determination of C-reactive protein content in human whole blood, serum and plasma samples in vitro, mainly as a non-specific inflammatory index and for evaluating the risk of cardiovascular disease.
用于体外定量测定人全血、血清、血浆样本中C反应蛋白的含量，主要作为一种非特异性炎症指标和用于评价心血管疾病风险。
R1: Citrate buffer, ProClin300; R2: CRP antibody conjugated latex beads.
R1：柠檬酸盐缓冲液 、ProClin300； R2：CRP抗体偶联乳胶微球。
2027-12-04